ArticleCancer medicine2017
Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer.
Article in Cancer medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Blood-Based Cell-Free DNA in Ophthalmic Oncology.Translational vision science & technology · 2025Review
- Clinical application of ctDNA in early diagnosis, treatment and prognosis of patients with non-small cell lung cancer.Future oncology (London, England) · 2024Review
- Perioperative immunotherapy in stage IB-III non-small cell lung cancer: a critical review of its rationale and considerations.The Korean journal of internal medicine · 2023Review
- circulating tumor DNA in the immediate post-operative setting.medRxiv : the preprint server for health sciences · 2023Article
- Article
- Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review.Translational lung cancer research · 2022Review
- Circulating Tumor Cells and the Non-Touch Isolation Technique in Surgery for Non-Small-Cell Lung Cancer.Cancers · 2022Review
- Machine Learning Protocols in Early Cancer Detection Based on Liquid Biopsy: A Survey.Life (Basel, Switzerland) · 2021Review
- Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study.Translational lung cancer research · 2020Article
- The effect of surgical trauma on circulating free DNA levels in cancer patients-implications for studies of circulating tumor DNA.Molecular oncology · 2020Article
- Early circulating tumour DNA kinetics measured by ultra-deep next-generation sequencing during radical radiotherapy for non-small cell lung cancer: a feasibility study.Radiation oncology (London, England) · 2020Observational
- The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis.Molecular cancer · 2019Review
- Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives.Journal of thoracic disease · 2019Review
- Proof of concept: prognostic value of the plasmatic concentration of circulating cell free DNA in desmoid tumors using ddPCR.Oncotarget · 2018Article
- The role of liquid biopsy in predicting post-operative recurrence of non-small cell lung cancer.Journal of thoracic disease · 2018Article
- Prognostic and predictive biomarkers post curative intent therapy.Annals of translational medicine · 2017Review
- Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer.Cancer medicine · 2017Article
- Baseline Plasma EGFR Circulating Tumour DNA Levels in a Pilot Cohort of EGFR-Mutant Limited-Stage Lung Adenocarcinoma Patients Undergoing Radical Lung Radiotherapy.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer cells release DNA fragments into plasma as circulating free DNA (cfDNA). However, quantitative measurement of tumor-derived DNA in cfDNA remains challenge. The purpose of this study was to quantitatively assess tumor-derived DNA in lung cancer patients. By optimizing competitive allele-specific TaqMan PCR (CAST-PCR), we assessed the copy number of mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) and epidermal growth factor receptor (EGFR) alleles in the pre/post surgery plasma of 168 lung cancer patients. An absolute quantitative PCR method was developed to assess the number of total cfDNA. All mutations detected in tumors were also found in the plasma after surgery. At the time of 30 days after surgery, EGFR mutation of circulating cell-free DNA was detected only in two patients who recurred in 4 months after surgery. Compared to that of normal control at 30 days after surgery, five patients who recurred in 4 months had significantly higher circulating cell-free DNA (P < 0.001), whereas six patients who recurred after 4 months (P = 0.207) and five patients without recurrence (P = 0.901) demonstrated significantly lower circulating cell-free DNA. Our findings suggest that cfDNA analysis in plasma is an alternative and supplement to tissue analysis and hold promise for clinical application. Stratification of patients according to cfDNA levels at 30 days after surgery might be helpful in selecting lung cancer patients for adjuvant therapy after surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.